Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). - Wikidata - wikimedia - TriplyDB

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

http://www.wikidata.org/entity/Q34828735

about

Anti-CD3 mAbs for treatment of type 1 diabetes Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury.Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune disease Immunotherapy of type 1 diabetes: where are we and where should we be going?Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells.Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity Challenges in the pursuit of immune tolerance.Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibody Immune intervention in type 1 diabetes.Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice TGF-beta, T-cell tolerance and anti-CD3 therapy.Achieving antigen-specific immune regulation Breakdown in peripheral tolerance in type 1 diabetes in mice and humans T cells in the control of organ-specific autoimmunity Functional avidity directs T-cell fate in autoreactive CD4+ T cells.TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues TGF-beta inhibitors for the treatment of cancer.T cell tolerance induced by therapeutic antibodies Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.Achieving antigen-specific tolerance in diabetes: regulating specifically.Antigen-specific induction of regulatory T cells for type 1 diabetes therapy.Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial Mechanistic basis of immunotherapies for type 1 diabetes mellitus Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?Regulatory CD4(+)CD25(+) T-cells are controlled by multiple pathways at multiple levels.Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies

P2860

Q28239248-6DAC3504-CB4C-4210-8E34-C9F4ADB09A03 Q28287737-61E954E0-DD49-4AEF-B90F-5CF9D8DF9780 Q28554636-36CFA35F-98A4-4F5C-AC9D-5AA94D41B993 Q33636716-398C5B8C-F255-4889-9446-98E68CA431A1 Q33637111-EF9D249F-2051-40BE-96AE-BE16311F185A Q33753720-2C860945-0730-4292-8907-12C76FE60C34 Q33782590-09BEA2AD-AE34-491D-BC82-4AA379F8CB6A Q33785953-B731C0A1-8802-4F27-A905-2028E6C4684A Q33815506-9CBEA902-B1CB-4CBF-911C-11FEA4D9EC87 Q34392230-90A7E083-952A-4D04-B85C-303AB715458D Q34421851-9F98606B-4D04-4272-AE9C-4469936FAEBB Q34546789-DC813BE3-CE63-4CCC-926E-4EDB6C407408 Q34613306-9DBAE7F7-7822-4ADD-BAB1-F8D0C9F64CD1 Q34630923-7AE0C765-6FC4-4104-B2DB-5A00CFFFF17F Q34831889-68E78F32-5952-4614-AEF4-EC3EDA3C616E Q34974448-87E4D174-E276-45EB-9236-226D50C8B79F Q35132238-E6079E7D-86FB-4410-9A6A-BA098E32D189 Q35142083-F9B9A3B1-FC0D-4FD9-8636-22A924B293AE Q35226251-BB2CFE7F-BF18-4D62-BF15-48BCD5C51EA4 Q35232365-7BCFF713-FC9B-442F-8F08-2D1EC5FD63D8 Q35612633-32451F16-B94D-4764-ADE2-395DB81C4F51 Q35616760-523A5023-8759-41D2-A01F-71EEECAFDF40 Q35628232-132E055B-9BB8-4D63-9D9E-F76A539F6648 Q35645080-FF910A5C-B4D6-455D-9AFB-F87CC696F340 Q35765731-6367A1C1-58F1-44E3-A645-90D23162DDB2 Q35836118-323BA954-1382-49AF-8FD8-1579730D549D Q35848366-9F37CEE6-8607-420D-92E0-3AC3DEEEB73C Q35924790-3815768A-E26D-43BC-B53F-7B3D1E045B7F Q36187040-8BDB1DA5-3197-42C1-B577-F43E730472C6 Q36251293-F6F2AA03-0639-42BD-9EAD-C7CD93A0B9DF Q36310443-7FB2B6AE-A431-4D30-9D43-520146399330 Q36327351-646F9649-7E61-417C-B296-F86284A8AF31 Q36327362-F1DBD023-9BE0-4FBE-B151-CB1C813720AE Q36327367-990BCEBB-CFA7-4A07-B8E1-1DDA25A37B34 Q36506677-DBEF27B0-E719-493A-B441-4A81E453E7A4 Q36510973-C00FAB27-7CC7-4125-9A1C-C3028BD2B5EE Q36698793-EFC0FD91-FB2D-4888-A715-92B4AD1C982A Q36782375-1DFBF3DA-6F67-4E82-95B1-49DECDE29E7E Q36844945-4B265AB4-9443-4A57-9357-5633572EF290 Q37106206-525BEB49-1CAB-450F-B0BC-BD94811B6AD3

P2860

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

http://www.wikidata.org/entity/Q34828735

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@ast

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@en

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@nl

type

label

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@ast

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@en

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@nl

prefLabel

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@ast

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@en

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@nl

P1433

Q34828735-E5408D8E-A057-4048-8D99-32FCF5D7F7D5

P1476

Q34828735-0267145F-29C8-4770-AEB8-65F9AE2F9CD2

P2093

Q34828735-32BBE942-6FAE-404E-97F5-579873A870B8

Q34828735-60A11213-1CEF-4810-87F2-27974B901C23

Q34828735-671FA909-8E8F-4CEE-9800-162741176820

Q34828735-67E11520-320D-4D70-94BD-F15419071E4A

Q34828735-84BAACCB-404D-44AC-BD95-BC606432FCBF

Q34828735-E4FEA109-0ACB-42FF-8503-06F0F9B1D295

P2860

Q34828735-06CAB3A9-275E-4B5C-99D4-2F2456A993D6

Q34828735-0B2C4122-83C0-42A0-9A90-48EB787C6528

Q34828735-0D4191DE-E5DF-4FF5-B561-8E21DAE4097A

Q34828735-0D74753E-E1B7-4734-8221-4B00E79734AF

Q34828735-11A1CC3D-7426-4117-830F-5F28FF27A51F

Q34828735-136B2B0C-81CC-44D3-90AF-E3D8AFE799E9

Q34828735-1BDD381E-8BA8-49F1-B7C5-693BAD51F1E3

Q34828735-271F0582-45D4-4080-80FD-F94BA6BE21F5

Q34828735-2956AC01-8FFF-48E1-AA6D-BBB5DC00091E

Q34828735-2E9BF68D-53F4-4C05-8603-0EE880E8B9A8

P304

Q34828735-9F62C0E8-361F-4CF6-9807-9EFF3C643E0C

P31

Q34828735-69F74881-0401-414A-AA98-BABB7AB07867

P356

Q34828735-16FDD45C-FEC5-4DE8-8230-BF6671C06DE7

P407

Q34828735-F439E643-A3C9-4207-99DC-5D44330D820A

P433

Q34828735-F1030232-2873-4D36-84CB-CE59A00F6B62

P478

Q34828735-2D2B7ABC-D69D-46B2-8AA6-6F583A33721F

P577

Q34828735-22D727ED-554A-4DE4-B246-1723BE50B756

P5875

Q34828735-F116A7A9-BA2E-491A-BF76-0299F70AB99B

P698

Q34828735-C89D3DEB-BBBF-47EF-A1D9-5B99DF30ABD5

P932

Q34828735-7B546932-CFCB-436B-9A4E-3108BA147016

P356

P1433

Journal of Clinical Investigation

P1476

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@en

P2093

Ena Poumian-Ruiz

http://www.w3.org/2001/XMLSchema#string

Fleur Francois

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Bluestone

http://www.w3.org/2001/XMLSchema#string

Joshua B Burton

http://www.w3.org/2001/XMLSchema#string

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Mariela Glandt

http://www.w3.org/2001/XMLSchema#string

P2860

Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling

Interleukin-10 and the interleukin-10 receptor

Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

Multiple immuno-regulatory defects in type-1 diabetes

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.

Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes

Regulatory T cells in autoimmmunity*.

P304

409-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI16090

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10916332

http://www.w3.org/2001/XMLSchema#string

P698

12569167

http://www.w3.org/2001/XMLSchema#string

P932

151852

http://www.w3.org/2001/XMLSchema#string